R. Ryan

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC

K. O'Byrne, S. Finn, S. Cuffe, 2016, Oncotarget.

Altered expression of ACOX2 in non-small cell lung cancer

Pilib Ó Broin, S. Gray, S. Finn, 2022, BMC Pulmonary Medicine.

Trial-in-progress: A pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC).

T. Greten, R. McDermott, D. Houlihan, 2021 .

MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer

K. O'Byrne, S. Gray, S. Finn, 2021, Translational lung cancer research.

Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC

K. O'Byrne, S. Gray, S. Finn, 2017, Oncotarget.

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC

K. O'Byrne, C. Blanco-Aparicio, S. Finn, 2021, Cancers.